PRTK - Paratek Pharmaceuticals, Inc.
| Previous Close | 3.9000 |
| Open | 3.8400 |
| Bid | 3.2000 x 900 |
| Ask | 5.8700 x 1100 |
| Day's Range | 3.6800 - 3.8600 |
| 52 Week Range | 2.8700 - 12.2000 |
| Volume | 279,201 |
| Avg. Volume | 345,509 |
| Market Cap | 122.532M |
| Beta (3Y Monthly) | 2.33 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.7620 |
| Earnings Date | May 2, 2018 - May 7, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | 2014-10-31 |
| 1y Target Est | 20.86 |
- Thomson Reuters StreetEvents
Edited Transcript of PRTK earnings conference call or presentation 6-Aug-19 8:30pm GMT
Q2 2019 Paratek Pharmaceuticals Inc Earnings Call
- Zacks
Paratek Pharmaceuticals (PRTK) Reports Q2 Loss, Tops Revenue Estimates
Paratek (PRTK) delivered earnings and revenue surprises of 12.07% and 9.95%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Paratek Pharmaceuticals Generates Net Revenues of $2.0 Million in the Second Quarter of 2019
-- NUZYRA® (omadacycline) Net Sales increased 26% to $1.7 Million in the Second Quarter of 2019 -- -- Over 50% of Commercial Lives in U.S. now have.
- GlobeNewswire
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Paratek Pharmaceuticals, Inc. (PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced that on July 31, 2019, the Company granted stock options and restricted stock units to one new employee of the Company. The stock options are to acquire, in the aggregate, 90,000 shares of the Company’s common stock at a per share exercise price of $3.23, the closing sales price on July 31, 2019, and shall vest over a four-year vesting period, under which 25% of the shares will vest after 12 months of employment, with the remaining shares vesting monthly thereafter over the remaining 36-month period, subject to the employee’s continuous service.
- GlobeNewswire
Paratek Pharmaceuticals to Report Second Quarter 2019 Financial Results on August 6, 2019
Domestic investors wishing to participate in the call should dial: 855-327-6838 and international investors should dial: 604-235-2082. Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics. The company’s lead commercial product, NUZYRA® (omadacycline), which has launched and is available in the United States, is a once-daily oral and intravenous antibiotic for the treatment of adults with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
- Zacks
Earnings Preview: Paratek Pharmaceuticals (PRTK) Q2 Earnings Expected to Decline
Paratek (PRTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Melinta (MLNT) Announces Preliminary Product Sales for Q2
Melinta (MLNT) announces preliminary sales for the second quarter. However, sales number suggests estimates miss for the quarter. Shares fall.
- Simply Wall St.
What Type Of Shareholder Owns Paratek Pharmaceuticals, Inc.'s (NASDAQ:PRTK)?
The big shareholder groups in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) have power over the company. Institutions...
- Insider Monkey
Here’s What Hedge Funds Think About Paratek Pharmaceuticals Inc (PRTK)
Concerns over rising interest rates and expected further rate increases have hit several stocks hard during the fourth quarter. Trends reversed 180 degrees during the first quarter amid Powell's pivot and optimistic expectations towards a trade deal with China. Hedge funds and institutional investors tracked by Insider Monkey usually invest a disproportionate amount of their […]
- PR Newswire
X-Biotix Therapeutics Joins Antimicrobials Working Group
WASHINGTON , July 1, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of X-Biotix Therapeutics, Inc. (X-Biotix) to its coalition of companies with the mission to ...
- GlobeNewswire
Paratek Pharmaceuticals Promotes Evan Loh, M.D. to Chief Executive Officer; Michael Bigham to Assume Role of Executive Chairman
Adam Woodrow Promoted to President & Retains Chief Commercial Officer Position Randy Brenner Promoted to Chief Development & Regulatory Officer BOSTON, June 25, 2019.
- American City Business Journals
Biotech companies dominate fastest-growing public companies list again
Biotech companies once again dominate the BBJ’s annual list of fastest-growing public companies in Massachusetts. Paratek Pharmaceuticals Inc., headquartered in Boston, ranks first on the list this year with revenue growth between 2016 and 2018 of 58,924 percent.
- PR Newswire
Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2019
64 Presentations by Coalition Members During the Annual Meeting WASHINGTON , June 20, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant ...
- PR Newswire
Antimicrobials Working Group Commends Senator Isakson and Senator Casey for Introducing Legislation to Improve Access to Innovative Therapies to Fight Drug-Resistant Infections
The DISARM Act of 2019 provides the framework needed to stabilize the antimicrobial ecosystem, spur development of new infection-fighting drugs, and preserve the effectiveness of existing medicines for ...
- Thomson Reuters StreetEvents
Edited Transcript of PRTK earnings conference call or presentation 8-May-19 8:30pm GMT
Q1 2019 Paratek Pharmaceuticals Inc Earnings Call
- Zacks
Paratek Pharmaceuticals (PRTK) Reports Q1 Loss, Tops Revenue Estimates
Paratek (PRTK) delivered earnings and revenue surprises of 8.33% and 79.55%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press
Paratek: 1Q Earnings Snapshot
On a per-share basis, the Boston-based company said it had a loss of $1.10. The results surpassed Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research ...
- GlobeNewswire
Paratek’s NUZYRA™ (omadacycline) Generates Net Sales of $1.3 Million in the First Eight Weeks on the U.S. Market
Paratek Pharmaceuticals, Inc. (PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today reported financial results and provided an update on corporate activities for the quarter ended March 31, 2019. “We are pleased with the results from the first eight weeks of the NUZYRA launch in the United States.
- Zacks
Analysts Estimate Paratek Pharmaceuticals (PRTK) to Report a Decline in Earnings: What to Look Out for
Paratek (PRTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Paratek Pharmaceuticals to Report First Quarter 2019 Financial Results on May 8, 2019
Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced the Company will host a conference call and live audio webcast on Wednesday, May 8, 2019 at 4:30 p.m. EDT to report its first quarter ended March 31, 2019 financial results and provide a corporate update. Domestic investors wishing to participate in the call should dial: 877-407-0792 and international investors should dial: 201-689-8263. Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics.
- Simply Wall St.
Should You Be Pleased About The CEO Pay At Paratek Pharmaceuticals, Inc.'s (NASDAQ:PRTK)
In 2014 Mike Bigham was appointed CEO of Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK). This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. Then we'l...
- GlobeNewswire
Paratek Pharmaceuticals Broadens Clinical Profile of NUZYRA™ (Omadacycline) with New ECCMID 2019 Data Presentations
- New microbiology data reinforce activity of NUZYRA against broad range of pathogens commonly associated with community-acquired infections - Study supports no dose.
- PR Newswire
Antimicrobials Working Group Highlights Member Company Participation at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
78 Presentations by Coalition Members During the Annual Meeting WASHINGTON , April 12, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant ...
- GlobeNewswire
Paratek Pharmaceuticals Presenting New Data from NUZYRA™ (Omadacycline) Development Program at ECCMID 2019
BOSTON, April 04, 2019 -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of.
- GlobeNewswire
Paratek Pharmaceuticals Receives American Chemical Society 2019 Heroes of Chemistry Award
BOSTON, April 01, 2019 -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of.
